Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:FOLD NASDAQ:KRTX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeFOLDAmicus Therapeutics$14.49$14.42$5.51▼$14.50$4.55B0.482.62 million shs5.29 million shsKRTXKaruna Therapeutics$329.83$327.01$158.38▼$329.99$12.58B1.18832,048 shsN/A7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceFOLDAmicus Therapeutics0.00%0.00%0.00%+0.84%+140.30%KRTXKaruna Therapeutics0.00%0.00%0.00%0.00%0.00%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeFOLDAmicus Therapeutics$14.49$14.42$5.51▼$14.50$4.55B0.482.62 million shs5.29 million shsKRTXKaruna Therapeutics$329.83$327.01$158.38▼$329.99$12.58B1.18832,048 shsN/A7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceFOLDAmicus Therapeutics0.00%0.00%0.00%+0.84%+140.30%KRTXKaruna Therapeutics0.00%0.00%0.00%0.00%0.00%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceFOLDAmicus Therapeutics 2.08Hold$14.560.50% UpsideKRTXKaruna Therapeutics 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest KRTX and FOLD Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/27/2026FOLDAmicus Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)(Data available from 6/15/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookFOLDAmicus Therapeutics$634.21M7.17$0.06 per share234.67$0.87 per share16.66KRTXKaruna Therapeutics$654K19,239.07N/AN/A$33.24 per share9.92Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateFOLDAmicus Therapeutics-$27.11M-$0.08N/A18.82N/A-4.27%4.15%1.09%N/AKRTXKaruna Therapeutics-$433.68M-$11.72N/AN/AN/AN/A-31.63%-30.38%N/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthFOLDAmicus TherapeuticsN/AN/AN/AN/AN/AKRTXKaruna TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioFOLDAmicus Therapeutics1.432.841.88KRTXKaruna TherapeuticsN/A19.3119.31Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipFOLDAmicus TherapeuticsN/AKRTXKaruna TherapeuticsN/AInsider OwnershipCompanyInsider OwnershipFOLDAmicus Therapeutics2.20%KRTXKaruna Therapeutics13.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableFOLDAmicus Therapeutics480314.00 million307.09 millionOptionableKRTXKaruna Therapeutics33938.15 million33.16 millionOptionableKRTX and FOLD HeadlinesRecent News About These CompaniesKaruna head, Teva alums meet minds to launch schizophrenia-focused biotech Syremis with $165M series ADecember 19, 2025 | fiercebiotech.comFKaruna Therapeutics’ Phase 3 Study on KarXT: A Potential Game-Changer for Alzheimer’s PsychosisAugust 12, 2025 | tipranks.comKaruna Therapeutics’ Phase 3 Study on KarXT: A Potential Game-Changer for Alzheimer’s PsychosisJuly 17, 2025 | tipranks.comKaruna Therapeutics’ Phase 3 Study on KarXT: A Potential Game-Changer for Alzheimer’s PsychosisJuly 4, 2025 | tipranks.comKaruna Therapeutics Advances Alzheimer’s Psychosis Treatment with KarXT StudyJune 27, 2025 | tipranks.comSeaport loads up $225M series B to continue Karuna veterans' voyage to clinical milestonesOctober 21, 2024 | fiercebiotech.comFThis FDA-approved drug promises a new way to treat schizophreniaSeptember 30, 2024 | msn.comFDA approves Bristol Myers and Karuna's schizophrenia drug, in milestone for psychiatrySeptember 27, 2024 | endpts.comEEndpoints 11 winner Seaport Therapeutics: The Karuna team is back with another big bet in neuroscienceSeptember 27, 2024 | endpts.comEBMS wins approval for schizophrenia drug acquired from KarunaSeptember 27, 2024 | msn.comBristol Myers Squibb's Karuna buyout pays off with FDA approval for novel schizophrenia med CobenfySeptember 27, 2024 | fiercepharma.comFBristol Myers to Purchase KarunaSeptember 13, 2024 | msn.comBMS wagers $14bn on Karuna’s schizophrenia drugJuly 25, 2024 | pharmaphorum.comPEx-Karuna team launch Seaport with $100m for psychiatry medsMay 10, 2024 | pharmaphorum.comPS&P 500 Q1 earnings estimated growth improves; stocks up for weekApril 26, 2024 | investing.comBristol Myers posts quarterly loss, lays out $1.5 billion cost-saving planApril 25, 2024 | investing.comAfter Karuna's acquisition, former CEO lands new gig at Cambridge biotechApril 22, 2024 | bizjournals.comNvelop and Seaport Raise $100M in Rounds, Tap Bluebird and Karuna ExecsApril 11, 2024 | biospace.comBSeaport Therapeutics has $100 million to develop new ways to treat mental disordersApril 9, 2024 | msn.comBig biotech names roll out Seaport Therapeutics, as interest in neuropsychiatric drugs swellsApril 9, 2024 | statnews.comSNew MarketBeat Followers Over TimeMedia Sentiment Over TimeKRTX and FOLD Company DescriptionsAmicus Therapeutics NASDAQ:FOLDAmicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset. It has collaboration and license agreements with the University of Pennsylvania to research and develop parvovirus gene therapy products; and GlaxoSmithKline. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Princeton, New Jersey.Karuna Therapeutics NASDAQ:KRTXKaruna Therapeutics, Inc., a clinical-stage biopharmaceutical company, creates and delivers transformative medicines for people living with psychiatric and neurological conditions. Its lead product candidate includes KarXT, an oral modulator of muscarinic receptors for the treatment of acute psychosis in patients with schizophrenia; and for the treatment of central nervous system disorders, such as negative and cognitive symptoms of schizophrenia and psychosis, as well as for the treatment of various peripheral tissues and dementia-related psychosis, including Alzheimer's disease. The company also focuses on developing other muscarinic-targeted drug candidates; and intends to develop lead candidature TRPC4/5 and KAR-2618 for the treatment of depressive disorder. Karuna Therapeutics, Inc. has a license agreement with Eli Lilly and Company, and Zai Lab (Shanghai) Co., Ltd; patent license agreement with PureTech Health LLC; and drug discovery partnership with Charles River Laboratories, as well as drug discovery collaboration with PsychoGenics, Inc. The company was formerly known as Karuna Pharmaceuticals, Inc. and changed its name to Karuna Therapeutics, Inc. in March 2019. Karuna Therapeutics, Inc. was incorporated in 2009 and is headquartered in Boston, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas What's Behind the Social Media Controversy Surrounding IonQ? Mission Control: Floating In SpaceX's Record-Breaking Orbit 3 Dividend Increases Investors Can Actually Trust RH’s Strong Q1 Still Leaves Investors With One Big Question SpaceX Rings the Bell and Shatters Every Record Adobe Stock Just Got Cheaper—Is Wall Street Missing the Story? Alphabet's Most Overlooked Division Just Had a Big Week Robinhood Wants a Bigger Role in IPOs—Here's Why It Matters Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
